 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--- CRTX--Cortexyme, Inc. Nasdaq: CRTX, a company advancing a pivotal trial in Alzheimers disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the selection of a lead 3CLpro inhibitor COR803 for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection. There continues to be a large unmet need for coronavirus treatment. The targ 